US · Healthcare · Biotechnology
EPS came in at -0.88 against a street estimate of -0.84 — a miss of 4.8%.
Analysts rate Uniqure NV a strong buy (11 buy, 2 hold, 0 sell out of 13) with an average price target of $60.68.
CONFIDENT uniQure won FDA alignment for accelerated approval of AMT-130 (Huntington's) based on 3-year data. BLA submission expected Q3 2026. Cash funded through 2030. Pipeline programs in epilepsy and Fabry show early promise. Q2 2026 U.S. and U.K. are near-term regulatory focus. European Medicines Agency engagement planned for 2027. Named-patient programs potential in Middle East, Latin America, Central/Eastern Europe post-approval. Analysts pressed on regulatory confidence, confirmatory trial operationalization, and commercial readiness. Management emphasized FDA alignment, global trial design to avoid retention risks, and intensive center-of-excellence engagement. No specifics on sample size, enrollment timeline, or year-1 patient throughput provided. 2026-07-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| venBio Select Advisor LLC | 9.70% |
| JPMorgan Chase & Co | 7.02% |
| RTW INVESTMENTS, LLC | 5.68% |
| State Street Corp | 4.19% |
| Aberdeen Group PLC | 4.11% |
| BlackRock Inc | 2.71% |
| Orbimed Advisors LLC | 2.61% |
| Jane Street Group LLC | 2.32% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • For the nine months ended September 30, 2026, total revenue was $14,599,000, up from $10,530,000 in the same period of 2025. • Ni | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $5.2 million, up from $3.7 million in the same period in 2025. • Net loss was $61.2 million, or $0 | 2026-11-04 |
| Reg FD disclosure · Q4 2026 HEADLINE NUMBERS • The FDA accepted uniQure’s Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy for | 2026-11-02 |
| Reg FD disclosure · Q3 2026 HEADLINE NUMBERS • uniQure N.V. filed a Form 8-K dated September 29, 2026. • The filing reports an update on ongoing clinical trials of AMT-130, the | 2026-09-29 |
| Reg FD disclosure · Q3 2026 UNIQURE N.V. DOCUMENT SUMMARY HEADLINE NUMBERS • Company: uniQure N.V., Netherlands-based biotech firm • Ticker: QURE (Nasdaq Global Select Market) | 2026-09-02 |
| Quarterly report · Q2 2026 UNIQURE N.V. – QUARTERLY REPORT SUMMARY Q2 2026 (Period ended June 30, 2026) --- HEADLINE NUMBERS • Cash & equivalents: $413.0 million (June 30, 20 | 2026-07-29 |
| Results announced · Q3 2026 UNIQURE Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 net loss: $81.1 million ($1.22 per share) vs. $37.7 million ($0.69 per share) i | 2026-07-29 |
| Material agreement · Q2 2026 UNIQURE N.V. FORM 8-K SUMMARY HEADLINE NUMBERS • Company completed underwritten public offering of 5,686,813 ordinary shares total (4,945,055 firm s | 2026-06-24 |
Readable in the app.
| Announcement | Date |
|---|---|
| Biologics License Application submitted for Huntington's disease treatment uniQure N.V. announced on September 2, 2026, that it has submitted a Biologics License Application (BLA) to the FDA for accelerated approval of AMT-130 (ifezuntirgene inilparvovec) to treat | 2026-09-02 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Uniqure NV — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.